Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NETs”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04566510
What this trial is testing

LLIN Evaluation in Uganda Project

Who this might be right for
Malaria
University of California, San Francisco 32,895
Testing effectiveness (Phase 2)UnknownNCT02294006
What this trial is testing

Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

Who this might be right for
Well Differentiated Pancreatic Endocrine Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 26
Post-approval studies (Phase 4)UnknownNCT01697852
What this trial is testing

The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention

Who this might be right for
Malaria
London School of Hygiene and Tropical Medicine 22,300
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Testing effectiveness (Phase 2)Study completedNCT03722511
What this trial is testing

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid Tumor of GI SystemDiarrhea+1 more
Lowell Anthony, MD 10
Not applicableStudy completedNCT02564393
What this trial is testing

Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
University Hospital, Tours 55
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Not applicableStudy completedNCT04696042
What this trial is testing

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Asan Medical Center 71
Testing effectiveness (Phase 2)Study completedNCT02299089
What this trial is testing

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Who this might be right for
AcromegalyNeuroendocrine Tumors
Camurus AB 12
Early research (Phase 1)Study completedNCT01364415
What this trial is testing

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 29
Testing effectiveness (Phase 2)Study completedNCT04362436
What this trial is testing

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets

Who this might be right for
Neuroendocrine TumorsLiver Metastases
Imperial College London 24
Not applicableActive Not RecruitingNCT03498040
What this trial is testing

Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors

Who this might be right for
Carcinoid Heart Disease
Hospices Civils de Lyon 670
Not applicableActive Not RecruitingNCT05064150
What this trial is testing

Neuroendocrine Tumors - Patient Reported Outcomes

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm+1 more
University of Iowa 2,539
Not applicableNot Yet RecruitingNCT06607198
What this trial is testing

Clinical-pathological Evaluation of Pit-NETs

Who this might be right for
PituitaryCancerNeuroendocrine Tumors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 940
Post-approval studies (Phase 4)Study completedNCT01595009
What this trial is testing

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 246
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Not applicableWithdrawnNCT03895463
What this trial is testing

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Who this might be right for
Neuroendocrine Tumors
Ipsen
Not applicableStudy completedNCT04157894
What this trial is testing

Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso

Who this might be right for
Malaria
PATH 5,606
Next Page